Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 11, 2019 22:33 ET | Source: Baozun Inc.

Baozun Sets New Total Order Value Record of RMB10.06 Billion on Singles Day 2019

SHANGHAI, China, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Baozun Inc. (Nasdaq: BZUN) ("Baozun" or the "Company"), the leading brand e-commerce service partner that helps brands execute their e-commerce...
November 11, 2019 11:00 ET | Source: Hua Medicine

华领医药双重机制葡萄糖激酶启动剂Dorzagliatin在未用药2型糖尿病患者中开展的单药治疗III期注册临床研究达到主要疗效终点

Dorzagliatin单药治疗III期注册临床研究（HMM0301）24周核心资料结果，达到研究主要疗效终点首次开展：针对2型糖尿病病因、专注修复血糖传感葡萄糖激酶、重塑血糖稳态的III期注册临床研究安全和耐受性好：dorzagliatin...
November 11, 2019 11:00 ET | Source: Hua Medicine

華領醫藥雙重機制葡萄糖激酶啟動劑Dorzagliatin在未用藥2型糖尿病患者中開展的單藥治療III期註冊臨床研究達到主要療效終點

Dorzagliatin單藥治療III期註冊臨床研究（HMM0301）24周核心資料結果，達到研究主要療效終點首次開展：針對2型糖尿病病因、專注修復血糖傳感葡萄糖激酶、重塑血糖穩態的III期註冊臨床研究安全和耐受性好：dorzagliatin...
November 11, 2019 11:00 ET | Source: Hua Medicine

Hua Medicine’s Pivotal Phase III Monotherapy Trial of Dorzagliatin, a Dual-Acting Glucokinase Modulator, Achieves Primary Efficacy Endpoint in Patients with Type 2 Diabetes

Phase III Monotherapy Trial (HMM0301) of Dorzagliatin Achieves Primary Efficacy Endpoint with 24-Week Topline ResultsFirst Phase III trial of a therapy targeting the underlying cause of type 2...
November 11, 2019 02:15 ET | Source: Hutchison China MediTech Limited

Chi-Med Announces NDA Acceptance in China for Surufatinib in Non-Pancreatic Neuroendocrine Tumors

LONDON, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that its New Drug Application (“NDA”) for surufatinib for the treatment of...
November 08, 2019 06:03 ET | Source: Hua Medicine

华领医药将于11月12日发布Dorzagliatin单药治疗III期临床试验24周顶线数据（HMM0301）

上海, Nov. 08, 2019 (GLOBE NEWSWIRE) -- 华领医药（香港主板股票代码：2552）是一家专注于研发治疗全球2型糖尿病原创口服新药的生物技术公司，总部位于上海。今天华领医药宣布，dorzagliatin单药治疗临床试验(HMM0301)的24周顶线数据将于2019年11月12日公布，管理层将通过电话会议陈述该试验结果并回答各种问题。日期:2019 年 11...
November 08, 2019 06:03 ET | Source: Hua Medicine

華領醫藥將於11月12日發佈Dorzagliatin單藥治療III期臨床試驗24周頂線資料（HMM0301）

上海, Nov. 08, 2019 (GLOBE NEWSWIRE) -- 華領醫藥（香港主機板股票代碼：2552）是一家專注於研發治療全球2型糖尿病原創口服新藥的生物技術公司，總部位於上海。今天華領醫藥宣佈，dorzagliatin單藥治療臨床試驗(HMM0301)的24周頂線資料將於2019年11月12日公佈，管理層將通過電話會議陳述該試驗結果並回答各種問題。日期:2019 年...
November 08, 2019 06:03 ET | Source: Hua Medicine

Hua Medicine to Release Phase III 24-Weeks Topline Data of Dorzagliatin Monotherapy Trial (HMM0301) on November 12

SHANGHAI, China, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Hua Medicine (HKEX: 2552), a Shanghai-based drug development company focused on developing a global first-in-class oral drug for the treatment of...
November 08, 2019 02:00 ET | Source: Huazhu Group Limited

Huazhu Group Limited Upgrades Management Team to Support Accelerated Growth Goal

SHANGHAI, China, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Huazhu Group Limited (NASDAQ: HTHT) (“Huazhu”, the “Company” or “our”), a leading and fast-growing hotel group, today announced its accelerated...
November 07, 2019 04:00 ET | Source: Baozun Inc.

Baozun to Announce Third Quarter 2019 Unaudited Financial Results on November 21, 2019

SHANGHAI, China, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Baozun Inc. (Nasdaq: BZUN) ("Baozun" or the "Company"), the leading brand e-commerce service partner that helps brands execute their e-commerce...